Evidence map›Paper›PMID 21069781›Full record

ArticleHippocampus2012

A novel non-CB1/TRPV1 endocannabinoid-mediated mechanism depresses excitatory synapses on hippocampal CA1 interneurons.

Jeffrey G Edwards, Helen E Gibson, Tyron Jensen, Fereshteh Nugent, Curtis Walther, Jacob Blickenstaff, Julie A Kauer

Abstract read
In one paragraph

Article in Hippocampus, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Inhibition of intracellular proton-sensitive CaActa pharmaceutica Sinica. B · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Functional diversity on synaptic plasticity mediated by endocannabinoids.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2012
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jeffrey G EdwardsDepartment of Molecular Pharmacology, Physiology and Biotechnology, Brown University, Providence, Rhode Island, USA. Jeffrey_Edwards@byu.edu
Helen E Gibson
Tyron Jensen
Fereshteh Nugent
Curtis Walther
Jacob Blickenstaff
Julie A Kauer
Brigham Young University · USBrown University · US

Funding

Inhibitory Synaptic Transmission, Stress and Drugs of AbuseR01DA011289 · NIDA · STANFORD UNIVERSITY · PI KAUER, JULIE A. · 1997 to 2023
$6.8M
Glutamatergic Synapses on Hippocampal InterneuronsR01NS050570 · NINDS · BROWN UNIVERSITY · PI KAUER, JULIE A. · 2005 to 2008
$933k
Characterization of CA 1 hippocampal interneuron LTDF32NS049779 · NINDS · BROWN UNIVERSITY · PI EDWARDS, JEFFREY G · 2005 to 2005
$31k
NIDA NIH HHS DA11289NIDA NIH HHS R01 DA011289NINDS NIH HHS F32 NS049779NINDS NIH HHS NS049779NINDS NIH HHS NS050570NINDS NIH HHS R01 NS050570
6 · The paper itself

Abstract

Endocannabinoids (eCBs) mediate various forms of synaptic plasticity at excitatory and inhibitory synapses in the brain. The eCB anandamide binds to several receptors including the transient receptor potential vanilloid 1 (TRPV1) and cannabinoid receptor 1 (CB1). We recently identified that TRPV1 is required for long-term depression at excitatory synapses on CA1 hippocampal stratum radiatum interneurons. Here we performed whole-cell patch clamp recordings from CA1 stratum radiatum interneurons in rat brain slices to investigate the effect of the eCB anandamide on excitatory synapses as well as the involvement of Group I metabotropic glutamate receptors (mGluRs), which have been reported to produce eCBs endogenously. Application of the nonhydrolysable anandamide analog R-methanandamide depressed excitatory transmission to CA1 stratum radiatum interneurons by ∼50%. The Group I mGluR agonist DHPG also depressed excitatory glutamatergic transmission onto interneurons to a similar degree, and this depression was blocked by the mGluR5 antagonist MPEP (10 μM) but not by the mGluR1 antagonist CPCCOEt (50 μM). Interestingly, however, neither DHPG-mediated nor R-methanandamide-mediated depression was blocked by the TRPV1 antagonist capsazepine (10 μM), the CB1 antagonist AM-251 (2 μM) or a combination of both, suggesting the presence of a novel eCB receptor or anandamide target at excitatory hippocampal synapses. DHPG also occluded R-methanandamide depression, suggesting the possibility that the two drugs elicit synaptic depression via a shared signaling mechanism. Collectively, this study illustrates a novel CB1/TRPV1-independent eCB pathway present in the hippocampus that mediates depression at excitatory synapses on CA1 stratum radiatum interneurons.

Indexed as

AnimalsArachidonic AcidsCA1 Region, HippocampalCannabinoid Receptor ModulatorsEndocannabinoidsExcitatory Postsynaptic PotentialsInterneuronsLong-Term Synaptic DepressionPatch-Clamp TechniquesPolyunsaturated AlkamidesRatsRats, Sprague-DawleyReceptor, Cannabinoid, CB1Receptors, Metabotropic GlutamateSignal TransductionSynapsesanandamideArachidonic AcidsCannabinoid Receptor ModulatorsEndocannabinoidsPolyunsaturated AlkamidesReceptor, Cannabinoid, CB1Receptors, Metabotropic GlutamateTrpv1 protein, ratTRPV Cation Channels

Identifiers

PMID21069781
PMCPMC3117951
OpenAlexW2126124111

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.